EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following the approval of a joint application submitted by MAPS PBC and COMPASS Pathways (NASDAQ: CMPS).
On March 3, the AMA published its Panel Actions summary which included the approval of the new Current Procedural Terminology (CPT) III code.
These types of codes are temporary and allotted to emerging technologies, services and procedures aimed at data collection to substantiate more widespread usage or to provide documentation for Food and Drug Administration (FDA) approval process. Read more HERE.
Amanita Muscaria Mushrooms Are Taking The Lead In Markets As Research Ramps Up
Amanita Muscaria is the only kind of mushroom currently legal. As its health benefits are regularly being confirmed in studies, demand for related products is rapidly growing.
This scenario has compelled Colorado-based Panacea Life Sciences (OTCMKTS: PLSH) to conduct research and formulation design for product development expansion.
Amanita Muscaria contains ibotenic acid, muscarine, muscazone and muscimol. Their pharmacology is “psychoactive” in the sense that it produces sedative and hallucinogenic effects as well as nausea, which is why it has been used for analgesic, anti-inflammatory and anxiolytic purposes at different doses, as well …